Novavax vaccine shows 90.4% efficacy in U.S. and Mexico Phase III trials
Phase III clinical trials for the Novavax COVID-19 vaccine candidate concluded in the U.S. and Mexico, reporting an overall efficacy of 90.4%. The vaccine demonstrated 86.3% efficacy against the B.1.1.7 Alpha variant.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthNovavax vaccine shows 90.4% efficacy in U.S. and Mexico Phase III trials
Sign in or subscribeBrowse free archive reportsPhase III clinical trials for the Novavax COVID-19 vaccine candidate concluded in the U.S. and Mexico, reporting an overall efficacy of 90.4%. The vaccine demonstrated 86.3% efficacy against the B.1.1.7 Alpha variant.